The Hematology segment focuses on the research, development, and commercialization of therapies for blood disorders, including hemophilia. Sobi's R&D activities in this area involve developing novel factor replacement therapies and gene therapies. The company utilizes advanced protein engineering and formulation technologies to improve the efficacy and safety of its products. This segment addresses the needs of patients with hemophilia A and B, providing treatments like Elocta and Alprolix. Sobi's market position is strong due to its established presence and partnerships in the hemophilia market. Future opportunities include expanding the product portfolio and exploring new treatment modalities. Regulatory aspects involve obtaining approvals from agencies like the FDA and EMA. Sobi collaborates with other pharmaceutical companies and research institutions to advance its hematology pipeline.

The Immunology segment concentrates on developing and commercializing treatments for immune-related disorders. Sobi's R&D efforts include the development of therapies for conditions like cryopyrin-associated periodic syndrome (CAPS) and rheumatoid arthritis. The company employs various technologies, including monoclonal antibody development and protein-based therapeutics. This segment aims to improve the lives of patients suffering from chronic inflammatory diseases. Sobi's market position is strengthened by its focus on specialty care and its partnerships with other companies. Future opportunities include expanding the product portfolio and exploring new treatment modalities. Regulatory aspects involve obtaining approvals from agencies like the FDA and EMA. Sobi collaborates with other pharmaceutical companies and research institutions to advance its immunology pipeline.

The Rare Diseases segment is dedicated to developing and commercializing treatments for rare and often life-threatening conditions. Sobi's R&D activities include the development of therapies for genetic and metabolic diseases, such as hereditary tyrosinemia type 1 (HT-1) and hemophagocytic lymphohistiocytosis (HLH). The company utilizes advanced technologies, including small molecule drug development and protein-based therapeutics. This segment aims to address the unmet medical needs of patients with rare diseases, improving their quality of life and survival rates. Sobi's market position is enhanced by its focus on orphan drugs and its partnerships with patient advocacy groups. Future opportunities include expanding the product portfolio and exploring new treatment modalities. Regulatory aspects involve obtaining orphan drug designations and approvals from agencies like the FDA and EMA. Sobi collaborates with other pharmaceutical companies and research institutions to advance its rare disease pipeline.